There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Cinacalcet
CAS No.: 226256-56-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Cinacalcet (AMG 073) is an orally active, allosteric agonist of the calcium receptor (CaR), used for cardiovascular disease research.
Synonyms: AMG 073; Sensipar; Cin
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 226256-56-0 |
Formula : | C22H22F3N |
M.W : | 357.41 |
SMILES Code : | FC(C1=CC(CCCN[C@@H](C2=C3C=CC=CC3=CC=C2)C)=CC=C1)(F)F |
Synonyms : |
AMG 073; Sensipar; Cin
|
MDL No. : | MFCD09840270 |
GHS Pictogram: |
![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H302-H315-H319-H360 |
Precautionary Statements: | P201-P202-P264-P270-P280-P301+P312-P302+P352-P305+P351+P338-P308+P313-P321-P330-P332+P313-P337+P313-P362+P364-P405-P501 |
Class: | 6.1 |
UN#: | 2810 |
Packing Group: | Ⅲ |
In Vitro:
Concentration | Treated Time | Description | References |
Enterococcus faecalis (LRE 16C352) | 12.5 mg/mL | 16 hours | Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells | PMC10074155 |
Enterococcus faecalis (E. faecalis 16C51) | 12.5 mg/mL | 16 hours | Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells | PMC10074155 |
Staphylococcus aureus (MRSA YUSA145) | 12.5 mg/mL | 16 hours | Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells | PMC10074155 |
Staphylococcus aureus (MSSA CHS101) | 12.5 mg/mL | 16 hours | Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells | PMC10074155 |
Osteoclasts | 400 nM | 18 hours | Cinacalcet significantly reduced the bone resorption area and increased Wnt10b expression and release from osteoclasts. | PMC6600662 |
MDCK cells | 30 μM | 20 minutes | Cinacalcet inhibited forskolin-induced cAMP elevation by 60%, and its effect was completely reversed by IBMX | PMC10922239 |
MDCK cells | 30 μM | 20 minutes | Cinacalcet inhibited forskolin-induced Cl− secretion and CFTR activity, reducing short-circuit current changes by ~70% | PMC10922239 |
Human intestinal T84 cells | 30 μM | 20 minutes | Cinacalcet pretreatment inhibited all 3 components of forskolin and cholera toxin-induced secretory short-circuit currents (Isc) (CFTR, Clc-2, and K+ channels) by ∼75%. | PMC11071643 |
HBE cells | 30 μM | 20 minutes | Cinacalcet pretreatment significantly inhibited CFTR-mediated Cl- secretion but had no significant effect on ENaC or CaCC activities. | PMC7934922 |
FRT cells | 30 μM | 20 minutes | Cinacalcet pretreatment did not affect CFTR-mediated Cl- conductance, indicating its inhibitory effect on CFTR is dependent on CaSR activation. | PMC7934922 |
T84 cells | 10 μM and 30 μM | 20 minutes | Cinacalcet significantly inhibited forskolin-induced Cl- secretion, reducing ISC increase by approximately 50% and 85%, respectively. | PMC7934922 |
HEK293 cells | 10 nM | 20 minutes | To evaluate the effect of Cinacalcet on signaling in Gα11 Asp195Gly mutant cells, results showed that 10 nM Cinacalcet corrected the signaling abnormalities in mutant cells. | PMC5846897 |
Bone marrow-derived macrophages (BMDMs) | 0.1, 1, 5 μM | 24 hours | Cinacalcet significantly reduced the TNFα-induced mRNA expression and secretion levels of inflammatory cytokines IL-1β and IL-6. | PMC8645985 |
RAW264.7 cells | 0.1, 1, 5 μM | 24 hours | Cinacalcet significantly reduced the TNFα-induced mRNA expression and secretion levels of inflammatory cytokines IL-1β and IL-6. | PMC8645985 |
HEK293 cells | 100nM | 30 minutes | To evaluate the effect of Cinacalcet on intracellular calcium signaling in HEK293 cells expressing wild-type and mutant CaSR, results showed that Cinacalcet could correct the abnormal intracellular calcium signaling caused by Ile555Thr mutation. | PMC7615553 |
Human primary ADPKD cells | 3 μM | 6 days | Cinacalcet inhibited forskolin-induced cyst enlargement by 60% and reduced cell proliferation | PMC10922239 |
MDCK cells | 1-10 μM | 6 days | Cinacalcet concentration-dependently reduced cell proliferation, cyst formation and cyst enlargement by up to 50% without affecting cell viability | PMC10922239 |
Cells expressing the calcium-sensing receptor and AP2-sigma mutants | 10 nM | Corrected the abnormal intracellular calcium signaling and MAPK responses to extracellular calcium | PMC4972445 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
C57BL/6 mice | DSS-induced colitis model | Oral gavage | 0.1, 1, 10 mg/kg | Daily administration until the end of the experiment | Cinacalcet significantly reduced the disease activity index score, prevented colon shortening, diminished inflammatory cell infiltration, and protected the structural integrity of the intestinal wall. Additionally, Cinacalcet reduced the production of inflammatory cytokines TNFα, IL-1β, and IL-6 in the colon and sera of mice with DSS-induced colitis. | PMC8645985 |
Mice | Intestinal closed loop models of cholera and traveler’s diarrhea | Intraperitoneal injection | 1, 10 and 30 mg/kg | Single dose, lasting 3 hours | Cinacalcet at 30 mg/kg significantly inhibited intestinal fluid accumulation induced by cholera toxin and STa toxin, reducing fluid accumulation by approximately 75% and 60%, respectively. | PMC7934922 |
Mice (BALB/c and C57BL/6J) | Pneumonia infection model and deep-seated infection model | Intraperitoneal injection | 10 mg/kg (pneumonia model) and 40 mg/kg (deep-seated infection model) | Every 24 hours for 2 days | Cinacalcet exhibited high anti-infective efficacy in vivo, comparable to vancomycin | PMC10074155 |
C57BL/6 mice | 5/6 nephrectomy CKD model | Oral gavage | 10 mg/kg/day | Once daily for 4 weeks | Cinacalcet significantly decreased serum PTH levels, reduced cortical porosity, and improved bone strength and stiffness. | PMC6600662 |
Mice | ADPKD mouse model | Subcutaneous injection | 20 mg/kg/day | Once daily for 7 days | Cinacalcet treatment reduced renal cyst enlargement by 20%, decreased kidney/body weight ratio and serum BUN | PMC10922239 |
Mice | Cholera toxin-induced secretory diarrhea model | Oral | 30 mg/kg | Single dose, evaluated at 20 hours | Cinacalcet inhibited forskolin-induced secretory Isc by ~60% in wild-type mice and had no antisecretory effect in intestinal epithelia-specific Casr knockout mice. In the suckling mouse model of cholera induced by oral cholera toxin, a single oral dose of cinacalcet reduced intestinal fluid accumulation by ~55% at 20 hours. | PMC11071643 |
Mice | Gna11+/195G and Gna11195G/195G mice | Oral | 30 mg/kg | Single dose, plasma samples collected at 0, 1, 2, 4, 6, and 24 hours post-dose | To evaluate the effect of Cinacalcet on hypercalcemia and PTH levels in Gna11 mutant mice, results showed that Cinacalcet significantly reduced plasma calcium and PTH concentrations. | PMC5846897 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02464072 | Hyperparathyroidism, Secondary | Not Applicable | Active, not recruiting | July 2019 | Brazil ... More >> University of Sao Paulo General Hospital Sao Paulo, SP, Brazil Less << |
NCT01073462 | - | Completed | - | - | |
NCT01073462 | - | Completed | - | Austria ... More >> Site Reference ID/Investigator# 27447 Graz, Austria, 8010 Site Reference ID/Investigator# 49182 Graz, Austria, 8020 Site Reference ID/Investigator# 27483 Graz, Austria, 80360 Site Reference ID/Investigator# 52742 Graz, Austria, 8052 Site Reference ID/Investigator# 27487 Innsbruck, Austria, 6020 Site Reference ID/Investigator# 36983 Linz, Austria, 4010 Site Reference ID/Investigator# 27484 Linz, Austria, 4020 Site Reference ID/Investigator# 27485 Rottenmann, Austria, 8786 Site Reference ID/Investigator# 27446 Vienna, Austria, 1030 Site Reference ID/Investigator# 53469 Vienna, Austria, 1090 Site Reference ID/Investigator# 27482 Vienna, Austria, 1130 Site Reference ID/Investigator# 10981 Vienna, Austria, 1220 Less << | |
NCT02102204 | Hyperparathyroidism, Secondary | Phase 3 | Completed | - | - |
NCT02102204 | - | Completed | - | - | |
NCT03527511 | - | Recruiting | May 14, 2020 | France ... More >> Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant - Bron. Recruiting Bron, France, 69677 Contact: Justine BACCHETTA, Pr 04 27 85 61 30 ext +33 justine.bacchetta@chu-lyon.fr Principal Investigator: Justine BACCHETTA, Pr Sub-Investigator: Bruno RANCHIN, Dr Sub-Investigator: Anne-Laure SELIER-LECLERC, Dr Sub-Investigator: Aurélia BERTHOLET-THOMAS, Dr Sub-Investigator: Elodie CHEYSSAC, Dr Sub-Investigator: Corentin TANNE, Dr Less << | |
NCT01717989 | - | Completed | - | - | |
NCT01421407 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Parathyroid Hyperplasia Less << | Not Applicable | Withdrawn | - | Italy ... More >> Ospedale generale regionale "Miulli" Acquaviva delle Fonti, Italy, 70021 Ospedale Maggiore Policlinico Mangiagalli e Regina Elena Milano, Italy, 20122 Spain Hospital Universitario Marquès de Valdecilla Santander, Cantabria, Spain, 39008 Less << |
NCT03603444 | - | Completed | - | Italy ... More >> Azienda Ospedaliero - Universitaria di Modena Modena, Italy, 41124 Less << | |
NCT00189501 | - | Completed | - | - | |
NCT01717989 | - | Completed | - | - | |
NCT00110656 | - | Completed | - | - | |
NCT02273570 | Hyperparathyroidism, Secondary | Not Applicable | Unknown | March 2017 | Italy ... More >> Azienda Ospedaliera Sant'Anna Recruiting San Fermo della battaglia (CO), Italy, 22020 Contact: Simona Urbano +39.031.585.8947 comitato.etica@hsacomo.org Principal Investigator: Antonio Bellasi, MD Principal Investigator: Claudio Minoretti, MD Less << |
NCT00042432 | Secondary Hyperparathyroidism ... More >> Chronic Renal Insufficiency Less << | Phase 2 | Completed | - | - |
NCT01011699 | Chronic Renal Failure ... More >> Hemodialysis Less << | Phase 3 | Terminated(Financial problem) | - | France ... More >> Centre Hospitalier Général Soissons, Aisne, France, 02009 Centre Hospitalier Lisieux, Calvados, France, 14100 ALURAD Limoges, Limousin, France, 87042 Centre Hospitalier Universitaire Reims, Marne, France, 51092 Association Régionale Promotion Dialyse à domicile (ARPDD) Reims, Marne, France Association pour le Développement de l'Hémodialyse Hénin-Beaumont, Nord-Pas de Calais, France, 62110 Polyclinique de la Louvière Lille, Nord, France, 59000 CHRU Lille, Nord, France, 59037 Hôpital Victor Provo Roubaix, Nord, France, 59056 Centre Hospitalier Général Valenciennes, Nord, France, 59322 Centre Hospitalier Général Beauvais, Oise, France, 60000 Clinique Saint Côme Compiegne, Oise, France, 60200 Centre Hospitalier Général Creil, Oise, France, 60100 Clinique du Bois Bernard Bois Bernard, Pas de calais, France, 62320 Centre Hospitalier Boulogne sur mer, Pas de calais, France, 62200 Centre Hospital-Universitaire d'Amiens Amiens, Picardie, France, 80054 Clinique de l'Europe Rouen, Seine maritime, France, 76040 Centre Hospitalier Cambrai, France, 59407 Less << |
NCT00037518 | Hyperparathyroidism|Parathyroi... More >>d Neoplasms Less << | PHASE4 | COMPLETED | - | - |
NCT02216656 | Secondary Hyperparathyroidism | Phase 2 | Completed | - | Japan ... More >> For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Tokyo, Japan Less << |
NCT02440581 | Kidney Failure, Chronic | Not Applicable | Recruiting | June 2020 | United States, Kentucky ... More >> University of Kentucky Recruiting Lexington, Kentucky, United States, 40536 Contact: Nedda Hughes, PA 859-218-1509 nkhugh1@uky.edu Contact: Tara Spach 859-323-2672 tara.spach@uky.edu Less << |
NCT00656032 | End Stage Renal Disease | Phase 2 | Completed | - | United States, Tennessee ... More >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Less << |
NCT00037635 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << | Phase 3 | Completed | - | - |
NCT00395902 | - | Completed | - | - | |
NCT01100723 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 4 | Completed | - | United States, Virginia ... More >> Lynchburg Nephrology Associates, P.L.L.C. Lynchburg, Virginia, United States, 24501 Less << |
NCT00042432 | - | Completed | - | - | |
NCT02525796 | Primary Hyperparathyroidism | Phase 2 Phase 3 | Recruiting | December 2020 | United States, Massachusetts ... More >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Molly Connors 617-732-5186 Less << |
NCT01932970 | Hyperparathyroidism, Secondary | Phase 3 | Completed | - | - |
NCT00325104 | Hypercalcemia ... More >> Familial Primary Hyperparathyroidism Less << | Phase 3 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT02133404 | Secondary Hyperparathyroidism | Phase 2 | Completed | - | Japan ... More >> Chubu, Japan Chugoku, Japan Kanto, Japan Kyushu, Japan Shikoku, Japan Tohoku, Japan Less << |
NCT00042653 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << | Phase 3 | Completed | - | - |
NCT00132431 | Kidney Disease|Secondary Hyper... More >>parathyroidism|Chronic Kidney Disease Less << | PHASE4 | COMPLETED | 2025-07-05 | - |
NCT01932970 | - | Completed | - | - | |
NCT01599962 | Memory Functions | Phase 2 | Completed | - | Switzerland ... More >> University of Basel, Division of Cognitive Neuroscience Basel, Switzerland, 4055 Less << |
NCT00110929 | End Stage Renal Disease | PHASE2 | COMPLETED | - | - |
NCT01573520 | Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 4 | Completed | - | Switzerland ... More >> Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, 1011 Less << |
NCT01100723 | - | Completed | - | - | |
NCT01748812 | Osteomalacia | Phase 1 | Terminated | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT00527085 | Renal Osteodystrophy | Phase 2 | Completed | - | - |
NCT00261950 | Secondary Hyperparathyroidism | Phase 2 | Completed | - | - |
NCT02227264 | Primary Hyperparathyroidism | Not Applicable | Unknown | December 2016 | Sweden ... More >> Karolinska University Hospital Recruiting Stockholm, Sweden, 171 76 Contact: Inga-Lena Nilsson, Assoc.prof. inga-lena.nilsson@ki.se Less << |
NCT00261950 | - | Completed | - | - | |
NCT00113945 | End Stage Renal Disease | PHASE2 | COMPLETED | - | - |
NCT00135304 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | - |
NCT00110890 | End Stage Renal Disease | Phase 4 | Completed | - | - |
NCT00415584 | Secondary Hyperparathyroidism ... More >> Hypercalcemia Less << | Not Applicable | Withdrawn(low enrollment) | - | United States, New York ... More >> Montefiore Medical Center Bronx, New York, United States, 10467 Less << |
NCT02549391 | Secondary Hyperparathyroidism | Phase 2 Phase 3 | Completed | - | Japan ... More >> For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Tokyo, Japan Less << |
NCT00527267 | Hyperparathyroidism | Phase 3 | Completed | - | - |
NCT00110890 | - | Completed | - | - | |
NCT00446329 | Secondary Hyperparathyroidism | Phase 4 | Terminated(due to financial pr... More >>oblems) Less << | - | Greece ... More >> Papageorgiou General Hospital Thessaloniki, Greece, 56403 Less << |
NCT00803712 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Less << | Phase 4 | Completed | - | - |
NCT00336739 | Healthy | Not Applicable | Completed | - | United States, Massachusetts ... More >> Human Nutrition Research Center on Aging at Tufts University Boston, Massachusetts, United States, 02111 Less << |
NCT00113958 | End Stage Renal Disease | PHASE2 | COMPLETED | - | - |
NCT01460030 | Parathyroid Carcinoma ... More >> Hypercalcemia Primary Hyperparathyroidism Less << | Phase 3 | Completed | - | Japan ... More >> Sendai, Japan Less << |
NCT00975000 | Chronic Allograft Nephropathy ... More >> Chronic Kidney Disease Chronic Renal Failure Disordered Mineral Metabolism End Stage Renal Disease Hyperparathyroidism Hypophosphatemia Kidney Disease Kidney Transplantation Post Renal Transplantation Less << | Phase 3 | Completed | - | - |
NCT01181531 | Hyperparathyroidism, Secondary | Phase 4 | Completed | - | - |
NCT00803712 | - | Completed | - | - | |
NCT00094484 | Kidney Disease ... More >> Chronic Kidney Disease Less << | Phase 3 | Completed | - | - |
NCT01181531 | - | Completed | - | - | |
NCT00936650 | Hyperparathyroidism, Primary | Phase 2 | Completed | - | - |
NCT00975000 | - | Completed | - | - | |
NCT01277510 | Chronic Kidney Disease ... More >> Hyperparathyroidism Hyperparathyroidism, Secondary Kidney Disease Secondary Hyperparathyroidism Less << | Phase 3 | Terminated(Study was suspended... More >> in agreement between sponsor and FDA due to concerns about the study design after a fatality had occurred in the presence of hypocalcemia.) Less << | - | - |
NCT00345839 | - | Completed | - | - | |
NCT01277510 | - | Terminated(Study was suspended... More >> in agreement between sponsor and FDA due to concerns about the study design after a fatality had occurred in the presence of hypocalcemia.) Less << | - | - | |
NCT03027557 | Primary Hyperparathyroidism ... More >> Parathyroid Adenoma Parathyroid Hyperplasia Less << | Phase 3 | Enrolling by invitation | March 30, 2019 | Denmark ... More >> Aalborg University Hospital Aalborg, Denmark, 9000 Less << |
NCT00952094 | Healthy | Phase 1 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Clinical Trial Center Seoul, Korea, Republic of Less << |
NCT01250405 | Chronic Kidney Disease | Phase 4 | Completed | - | Canada, Quebec ... More >> Karine Marquis Québec, Quebec, Canada, G1R2J6 Less << |
NCT00977080 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Hemodialysis Less << | Phase 4 | Completed | - | - |
NCT00345839 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 3 | Completed | - | - |
NCT00928408 | Hyperparathyroidism, Primary | COMPLETED | 2025-02-12 | - | |
NCT00977080 | - | Completed | - | - | |
NCT01054079 | Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Less << | Phase 2 | Completed | - | United States, North Carolina ... More >> Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 Less << |
NCT00928408 | Hyperparathyroidism, Primary | COMPLETED | 2025-02-12 | - | |
NCT01178450 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | Spain ... More >> Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelone, Spain, 08907 Hospital Clinic de Barcelona Barcelona, Spain, 08036 Less << |
NCT00379899 | Chronic Kidney Disease ... More >> End Stage Renal Disease Coronary Artery Calcification Vascular Calcification Calcification Cardiovascular Disease Chronic Renal Failure Hyperparathyroidism Kidney Disease Nephrology Secondary Hyperparathyroidism Less << | Phase 4 | Completed | - | - |
NCT00117052 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << | Phase 3 | Completed | - | - |
NCT01896232 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 3 | Completed | - | - |
NCT00379899 | - | Completed | - | - | |
NCT01447368 | Kidney Failure ... More >> Secondary Hyperparathyroidism Vascular Diseases Less << | Not Applicable | Recruiting | December 2017 | Hong Kong ... More >> Queen Mary Hospital and Tung Wah Hospital Recruiting Hong Kong, Hong Kong, 0000 Contact: Angela YM Wang, MD, PhD 852-22554949 aymwang@hku.hk Principal Investigator: Angela YM Wang, MD, PhD Sub-Investigator: Wai-Kei Lo, FRCP Less << |
NCT01896232 | - | Completed | - | - | |
NCT00195936 | Hypophosphatemic Rickets, X-Li... More >>nked Dominant Less << | PHASE1 | COMPLETED | 2025-02-08 | Section of Pediatric Nephrolog... More >>y, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States Less << |
NCT00975221 | Hyperparathyroidism, Primary ... More >> Hypercalcemia Less << | Phase 3 | Completed | - | - |
NCT00975221 | - | Completed | - | - | |
NCT01101113 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Korea, Republic of, 110-744 Kyungpook National University Daegu, Korea, Republic of Gil Hospital Incheon, Korea, Republic of Hallym University Sacred Hospital Pyungchon, Korea, Republic of Seoul National University Bundang Hospital Seongnam, Korea, Republic of Eulji University Seoul, Korea, Republic of Samsung Medical Center Seoul, Korea, Republic of Less << |
NCT03774771 | Primary Hyperparathyroidism | Phase 2 | Completed | - | - |
NCT01054079 | - | Completed | - | - | |
NCT01011114 | Hypophosphatemia ... More >> Renal Transplant Less << | Not Applicable | Unknown | - | United States, New York ... More >> Montefiore Medical Center Recruiting Bronx, New York, United States, 10467 Principal Investigator: Maria Coco, MD,MS Less << |
NCT00844740 | Familial Hypophosphatemic Rick... More >>ets Less << | WITHDRAWN | 2012-03-01 | Children's Mercy Hospital, Kan... More >>sas City, Missouri, 64108, United States Less << | |
NCT01103206 | Parathyroid Hormone Suppressio... More >>n Test With Cinacalcet Less << | Phase 4 | Completed | - | France ... More >> University hospital Rouen, Haute Normandie, France, 76031 Less << |
NCT00936988 | Hyperparathyroidism, Primary | Phase 2 | Completed | - | - |
NCT00431496 | Anemia|Secondary Hyperparathyr... More >>oidism Less << | PHASE4 | COMPLETED | 2025-10-09 | - |
NCT01519037 | Relationship Between Calcimime... More >>tic and the RAAS Less << | Not Applicable | Completed | - | Switzerland ... More >> CHUV, service de néphrologie/hypertension Lausanne, Vaud, Switzerland, 1011 Less << |
NCT02138838 | - | Terminated(Sponsor decision) | - | - | |
NCT01439867 | Chronic Kidney Disease ... More >> Hyperparathyroidism, Secondary Less << | Phase 2 | Terminated(Sponsor decision) | - | - |
NCT02338934 | Secondary Hyperparathyroidism | Phase 4 | Unknown | January 2017 | Malaysia ... More >> Clinical Research Centre, Penang Hospital George Town, Penang, Malaysia, 10990 Penang Hospital Not yet recruiting George Town, Penang, Malaysia, 10990 Contact: Ong Loke Meng, FRCS 00 604 2225333 ext 767 onglm@crc.gov.my Less << |
NCT01143987 | Hyperparathyroidism|Arterial S... More >>tiffness Less << | PHASE4 | COMPLETED | 2025-02-13 | Prince of Wales Hospital, Chin... More >>ese University of Hong Kong, Shatin, New Territories, SAR, Hong Kong Less << |
NCT01439867 | - | Terminated(Sponsor decision) | - | - | |
NCT03776058 | Primary Hyperparathyroidism | Phase 2 | Completed | - | - |
NCT03123406 | Hyperparathyroidism; Secondary... More >>, Renal Less << | Phase 4 | Recruiting | September 27, 2019 | China, Jiangsu ... More >> Nanjing Jinling Hospital Recruiting Nanjing, Jiangsu, China, 210002 Contact: Zhihong Liu Less << |
NCT02417389 | Hyperparathyroidism, Primary ... More >> Osteoporosis Less << | Phase 4 | Completed | - | Italy ... More >> Istituto Auxologico Italiano IRCCS Milano, Italy, 20145 Less << |
NCT01290029 | Chronic Kidney Disease|Hyperpa... More >>rathyroidism, Secondary|Secondary Hyperparathyroidism Less << | PHASE1 | COMPLETED | 2015-09-23 | Research Site, Los Angeles, Ca... More >>lifornia, 90095, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Heidelberg, 69120, Germany|Research Site, Bristol, BS2 8BJ, United Kingdom|Research Site, Glasgow, G3 8SJ, United Kingdom|Research Site, Leeds, LS1 3EX, United Kingdom|Research Site, Manchester, M13 9WL, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom Less << |
NCT01479088 | Secondary Hyperparathyroidism | Phase 2 Phase 3 | Unknown | December 2013 | Italy ... More >> U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII Active, not recruiting Bari, Italy, 70100 U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini Recruiting Genoa, Italy, 16147 Contact: Enrico E Verrina, MD +390105636276 enricoverrina@ospedale-gaslini.ge.it Contact: Ornella Della Casa Alberighi, MD PhD +390105636461 ornelladellacasa@ospedale-gaslini.ge.it Principal Investigator: Enrico E. Verrina, MD U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi Active, not recruiting Milan, Italy, 20100 U.O. Nefrologia e Dialisi - Ospedale Santobono Active, not recruiting Naples, Italy, 80100 U.O. Nefrologia e Dialisi - Ospedale Bambino Gesù Active, not recruiting Rome, Italy, 00100 Less << |
NCT03299244 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 3 | Recruiting | November 26, 2019 | - |
NCT02341417 | Secondary Hyperparathyroidism,... More >> Chronic Kidney Disease Less << | PHASE3 | COMPLETED | 2017-03-15 | Research Site, Los Angeles, Ca... More >>lifornia, 90027, United States|Research Site, Tucker, Georgia, 30084, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Minneapolis, Minnesota, 55454, United States|Research Site, Jackson, Mississippi, 39216, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, West Orange, New Jersey, 07052, United States|Research Site, New York, New York, 10029, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Cincinnati, Ohio, 45229, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43205, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Salt Lake City, Utah, 84113, United States|Research Site, Bruxelles, 1020, Belgium|Research Site, Praha 5, 150 06, Czechia|Research Site, Paris, 75015, France|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Marburg, 35043, Germany|Research Site, Athens, 11527, Greece|Research Site, Szeged, 6720, Hungary|Research Site, Genova, 16147, Italy|Research Site, Krakow, 30-663, Poland|Research Site, Lodz, 93-338, Poland|Research Site, Moscow, 107014, Russian Federation|Research Site, Saint Petersburg, 198205, Russian Federation|Research Site, Samara, 443095, Russian Federation|Research Site, Kyiv, 01135, Ukraine Less << |
NCT02341417 | Secondary Hyperparathyroidism,... More >> Chronic Kidney Disease Less << | PHASE3 | COMPLETED | 2017-03-15 | Research Site, Los Angeles, Ca... More >>lifornia, 90027, United States|Research Site, Tucker, Georgia, 30084, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Minneapolis, Minnesota, 55454, United States|Research Site, Jackson, Mississippi, 39216, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, West Orange, New Jersey, 07052, United States|Research Site, New York, New York, 10029, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Cincinnati, Ohio, 45229, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43205, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Salt Lake City, Utah, 84113, United States|Research Site, Bruxelles, 1020, Belgium|Research Site, Praha 5, 150 06, Czechia|Research Site, Paris, 75015, France|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Marburg, 35043, Germany|Research Site, Athens, 11527, Greece|Research Site, Szeged, 6720, Hungary|Research Site, Genova, 16147, Italy|Research Site, Krakow, 30-663, Poland|Research Site, Lodz, 93-338, Poland|Research Site, Moscow, 107014, Russian Federation|Research Site, Saint Petersburg, 198205, Russian Federation|Research Site, Samara, 443095, Russian Federation|Research Site, Kyiv, 01135, Ukraine Less << |
NCT02138838 | Chronic Kidney Disease, Second... More >>ary Hyperparathyroidism Less << | Phase 3 | Terminated(Sponsor decision) | - | - |
NCT01290029 | Chronic Kidney Disease|Hyperpa... More >>rathyroidism, Secondary|Secondary Hyperparathyroidism Less << | PHASE1 | COMPLETED | 2015-09-23 | Research Site, Los Angeles, Ca... More >>lifornia, 90095, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Heidelberg, 69120, Germany|Research Site, Bristol, BS2 8BJ, United Kingdom|Research Site, Glasgow, G3 8SJ, United Kingdom|Research Site, Leeds, LS1 3EX, United Kingdom|Research Site, Manchester, M13 9WL, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom Less << |
NCT00431496 | Anemia|Secondary Hyperparathyr... More >>oidism Less << | PHASE4 | COMPLETED | 2025-10-09 | - |
NCT05926570 | Drug Effect | PHASE4 | COMPLETED | 2024-01-22 | Sara Mabrouk Mohamed Elghoul, ... More >>Tanta, Egypt Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.80mL 0.56mL 0.28mL |
13.99mL 2.80mL 1.40mL |
27.98mL 5.60mL 2.80mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|